{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:25:24Z","timestamp":1792218324026,"version":"4.4.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":1528,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1093\/annonc\/mdv270","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T20:45:12Z","timestamp":1435092312000},"page":"1883-1889","source":"Crossref","is-referenced-by-count":615,"title":["First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study"],"prefix":"10.1016","volume":"26","author":[{"given":"Y.-L.","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-K.","family":"Liam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.H.","family":"How","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.L.","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv270_bb0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mdv270_bb0015","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/jcp.24238","article-title":"EGFR through STAT3 modulates \u0394N63&agr; expression to sustain tumor-initiating cell proliferation in squamous cell carcinomas","volume":"228","author":"Ripamonti","year":"2013","journal-title":"J Cell Physiol"},{"key":"10.1093\/annonc\/mdv270_bb0020","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv270_bb0025","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jnci\/dji055","article-title":"Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers","volume":"97","author":"Shigematsu","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdv270_bb0030","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/01.JTO.0000268677.87496.4c","article-title":"Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from the six medical centers in mainland China","volume":"2","author":"Wu","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdv270_bb0035","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.12659\/MSM.892476","article-title":"Efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with\/without EGFR mutations: evidence based on recent phase III randomized trials","volume":"20","author":"Zhang","year":"2014","journal-title":"Med Sci Monit"},{"key":"10.1093\/annonc\/mdv270_bb0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv270_bb0045","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv270_bb0050","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1158\/1078-0432.CCR-13-2233","article-title":"The impact of EGFR T790M mutations and BIM mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial","volume":"20","author":"Costa","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv270_bb0055","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv270_bb0060","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2013.07.003","article-title":"A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)","volume":"82","author":"Goto","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdv270_bb0065","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv270_bb0070","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label randomized phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv270_bb0075","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma.","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv270_bb0080","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv270_bb0085","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomized trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv270_bb0090","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-06-0462","article-title":"Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small-cell lung cancer patients treated with gefitinib or erlotinib","volume":"12","author":"Jackman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv270_bb0095","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.canlet.2008.02.064","article-title":"Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small-cell lung cancer patients is due to differential inhibition of downstream signals","volume":"265","author":"Zhu","year":"2008","journal-title":"Cancer Lett"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419317703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419317703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/9\/1883\/16701310\/mdv270.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T03:50:51Z","timestamp":1624506651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419317703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0923753419317703"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv270","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}